Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 35.50B | 34.76B | 31.83B | 28.29B | 27.05B | 29.82B |
Gross Profit | 16.64B | 16.15B | 14.49B | 13.41B | 13.58B | 14.72B |
EBITDA | 6.37B | 5.31B | 5.93B | 5.73B | 6.20B | 6.46B |
Net Income | 1.49B | 1.64B | 2.41B | 2.49B | 2.97B | 3.24B |
Balance Sheet | ||||||
Total Assets | 56.37B | 63.92B | 53.59B | 52.03B | 44.55B | 45.01B |
Cash, Cash Equivalents and Short-Term Investments | 1.95B | 2.96B | 2.73B | 5.68B | 4.08B | 6.06B |
Total Debt | 11.17B | 10.73B | 8.08B | 5.82B | 4.31B | 10.21B |
Total Liabilities | 27.35B | 30.71B | 23.18B | 21.58B | 19.38B | 23.53B |
Stockholders Equity | 28.82B | 33.01B | 30.17B | 30.04B | 24.75B | 21.02B |
Cash Flow | ||||||
Free Cash Flow | 2.70B | 3.27B | 1.60B | 2.23B | 5.63B | 6.15B |
Operating Cash Flow | 4.03B | 4.58B | 2.96B | 3.37B | 6.56B | 7.20B |
Investing Cash Flow | -5.85B | -4.55B | -6.54B | -1.47B | -1.33B | -1.99B |
Financing Cash Flow | 1.50B | 504.00M | 511.00M | -500.00M | -7.24B | -297.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | kr52.15B | 35.00 | 4.94% | 2.43% | 6.51% | -42.34% | |
66 Neutral | kr68.53B | 121.27 | 32.07% | 0.31% | 15.54% | 39.12% | |
65 Neutral | kr4.13B | 27.29 | 18.65% | 1.50% | 3.45% | 4.22% | |
64 Neutral | $6.20B | 55.06 | 5.17% | ― | 17.78% | -7.83% | |
54 Neutral | kr18.31B | 40.24 | 3.46% | 0.78% | 0.14% | ― | |
54 Neutral | kr1.51B | ― | -5.40% | ― | 16.27% | -22.61% | |
51 Neutral | $7.39B | 0.36 | -62.86% | 2.37% | 15.48% | -2.68% |
Getinge has announced that the EU CE Mark for its Cardiosave Intra-Aortic Balloon Pump has been reinstated by the EU Notified Body TÜV SÜD after addressing compliance gaps and implementing design improvements. This reinstatement allows Getinge to resume deliveries of the device to markets accepting the CE mark, ensuring healthcare professionals and patients have access to this critical cardiac care device.
The most recent analyst rating on ($SE:GETI.B) stock is a Sell with a SEK180.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.
Getinge has announced its Q2 Report 2025 will be released on July 18, 2025, followed by a conference call hosted by the company’s President & CEO and CFO. This event invites fund managers, analysts, and media to participate, potentially impacting stakeholders by providing insights into the company’s financial performance and strategic direction.
The most recent analyst rating on ($SE:GETI.B) stock is a Sell with a SEK190.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.